arry nicholas a saccomano insider trades for array biopharma inc bulletin investor alert new york markets close in market snapshot winners and losers expand keep open close expand keep open close expand keep open close expand keep open close expand keep open close array biopharma inc nasdaq arry go set alerts find a broker join td ameritrade market index overview profile news charts financials historical quotes analyst estimates options sec filings insiders marketstatecountryus array biopharma inc market open  real time quotes jul    pm arry quoteszigmancomposite   change   volume volume m real time quotes quoteszigmancomposite previous close     change   day low day high    week low  week high   insider activity individual nicholas a saccomano dr nick a saccomano is chief technology officer at somalogic inc and venture adviser at torrey pines investment inc he has worked in the pharmaceutical and biotech industries for the past twenty five years in that time he has managed drug discovery and development programs as well as the multidisciplinary core technology departments which support the r and d process he began his career at pfizer in  as part of cns drug discovery during his time in this group he had the good fortune to be part of teams that brought important new compounds to and through development in areas of great medical need like depression anxiety psychosis and alzheimera disease in  he was promoted to vice president in charge of discovery technology developing and managing a broad array of scientific disciplines including computational sciences genomics proteomics and highthroughput chemistry and biology in  was promoted to senior vice president at pfizer in charge strategic alliancesbusiness development in  he joined bend research a drug formulation and delivery company he remains an active advisor anor board member to many organizations and institutions including bend research sea lane biotechnologies chemdiv colorado bioscience association and northwestern university mr saccomano graduated from the state university of new york at buffalo in  with a bs in chemistry and subsequently from columbia university in  with phd in synthetic organic chemistry under the guidance of professor gilbert stork transactions date shares transaction value     derivativenonderivative trans at  per share      derivativenonderivative trans at  per share      derivativenonderivative trans at  per share      award at  per share      derivativenonderivative trans at  per share      derivativenonderivative trans at  per share  copyright  factset research systems inc all rights reserved source factset fundamentals officers and executives mr ron squarer chief executive officer  director mr andrew r robbins chief operating officer mr jason haddock chief financial officer dr victor sandor chief medical officer dr nicholas a saccomano chief scientific officer ms shalini sharp director ms tricia haugeto directorcorporate communications  ir ms kimberly pope vice presidenthuman resources mr john r moore secretary vice president  general counsel mr kyle a lefkoff chairman dr charles m baum independent director mr john a orwin independent director dr gwen a fyfe independent director mr gil j van lunsen independent director log in  pm edt july   marketstatecountryus new york open marketstatecountryuk london closed marketstatecountryjp tokyo closed marketstatecountryus   marketstatecountryuk   marketstatecountryjp   view all latest news newslatest pget ready for the lessprofitable amazon that you used to know pmattel stock price target cut to  from  at mkm partners pelectronic arts stock price target raised to  from  at mkm partners pexxon mobil stock price target cut to  from  at cfra pthe states where people spend the most on lotto tickets ptempur sealy stock price target raised to  from  at cfra pfiat chrysler gets approval to sell diesel cars pstarbucks’ teavana stores are the latest casualty at the mall phigh times is going public through a deal with a blankcheck company — and here’s what that means pintel earnings have message for amd and nvidia ‘bring it on’ pfoxconn’s history of broken promises casts a shadow on wisconsin news ptesla’s model  will be launched with panacheand a partylater friday pall the companies in jeff bezos’s empire in one large chart pbaker hughes data show weekly us oilrig count up a third time this month pamazon’s postearnings stock selloff is the smallest in seven years peuropean stocks end at month low as ubs falls tech worries weigh psurging australian dollar makes life tough for central bankers pus weekly active oilrig count up  at  baker hughes pus total weekly active drillingrig count up  at  baker hughes pseptember wti oil trades at bbl little changed from before the rig data loading more headlines dow quoteszigmanrealtime    nasdaq quoteszigmanrealtime    sp  quoteszigmanrealtime    kiosk   the retirementors retirement advice from our industry experts our team of financial professionals can help you plan and save for retirement then live well in it congakioskretirementorshtml    alerts congakioskalertshtml    virtual stock exchange our free stockmarket game • trade your virtual portfolio in real time • talk strategies in group discussions • find or create a game that suits you • use our learning center to improve congakioskgameshtml    location scouts housingmarket insights from our realty pros plus the latest data from realtorcom on  home markets across the us • see our complete real estate site congakioskrealestatehtml    lazy portfolios set it and forget it check out the returns on our  lazy portfolios that are made up of lowcost buyandhold index funds • how to create your own lazy portfolio congakiosklazyportfoliohtml  marketwatchcom site index topics help feedback newsroom roster media archive premium products mobile company info code of conduct corrections advertising media kit advertise locally reprints  licensing broker center your ad choices follow marketwatch rss podcasts wsjcom barrons online bigcharts virtual stock exchange financial news london wsjcom small business realtorcom mansion global copyright   marketwatch inc all rights reserved by using this site you agree to the terms of service privacy policy and cookie policy intraday data provided by six financial information and subject to terms of use historical and current endofday data provided by six financial information all quotes are in local exchange time realtime last sale data for us stock quotes reflect trades reported through nasdaq only intraday data delayed at least  minutes or per exchange requirements marketwatch top stories link to marketwatchs slice  stock market research top stocks quotes  news  fidelity investments skip to main content site navigation fidelitycom home customer service open an account refer a friend log in customer service open an account refer a friend log out search fidelitycom accounts  trade portfoliolog in required account positionslog in required tradelog in required active trader prolog in required transferlog in required cash managementlog in required billpaylog in required full viewlog in required profilelog in required account featureslog in required statementslog in required tax information retirement distributionslog in required offer see our featured trading offer learn more planning  advice what we offer financial basics building savings managing  growing wealth retirement life events news  research news watch listlog in required quotes alertslog in required mutual funds stocks fixed income bonds  cds etfs options markets  sectors ipos annuities learning center notebook notebook investment products mutual funds retirement  iras trading stocks fixed income bonds  cds etfs options sector investing cash management  credit cards managed accounts fidelity go  college savings annuities life insurance  long term care why fidelity the fidelity advantage planning  advice trading straightforward pricing insights  tools security  protection customer service open an account refer a friend log in customer service open an account refer a friend log out content and data provided by various third parties and fidelity − terms of use research  stocks  stock details enter company or symbol press down arrow for suggestions or escape to return to entry field view this information for the company or symbol snapshot detailed quote adv chart  technical news  events compare analyst opinions research reports key statistics earnings dividends ownership  insiders financial statements sec filings view this information for the company or symbol snapshot detailed quote advanced chart news analyst reports find symbol opens in new window stock research  ideas you are here stock research center my research screen  filter stock screeners preset expert strategies news  insights events calendar upgrades  downgrades explore firm research research firms research firm scorecards reports search related resources fidelity learning center us markets global markets sectors  industries stock research center not a fidelity customer no problem try our research for free without opening an account   trending stocks market movers top rated by sector orders by fidelity customers filters refresh equity summary score provided by starmine investing insights technical events provided by recognia as of  methodology recognia methodology bullish and bearish events of the day provide longshort trading ideas by identifying us stocks that have recently formed a bullish or bearish classic chart pattern patterns must have taken at least  days to form which draws out the more significant patterns for intermediate or longterm trend direction the list is then filtered to include stocks with a minimum  for bullish and  for bearish close price and a minimum  trading volume most recent patterns are listed first patterns on the same date are sorted using recognias proprietary quantitative algorithm to draw strong companies to the top and if further sorting is required for stocks with the same quantitative analysis result it is done by trading volume to draw highest volume stocks to the top vz log in for events urbn urbn syna ll hp log in for events alks cvrr cvrr esnd find out how to use fundamental analysis and technical analysis when evaluating stocks with the help of the fidelity learning center my research –  organize and track your favorite securities get started todays events as of  pm et  earnings  dividends  splits  upgrades  downgrades  economic  upcoming webinar events visit the learning center events page for a full list of upcoming webinars the equity summary score is provided for informational purposes only does not constitute advice or guidance and is not an endorsement or recommendation for any particular security or trading strategy the equity summary score is provided by thomson reuters starmine an independent company not affiliated with fidelity investmentsgics® global industry classification standards is an industry classification system developed by standard  poors in collaboration with morgan stanley capital international msci sp uses gics to determine the market segment to which a company is assignednews commentary including related symbols and events are from thirdparty sources unaffiliated with fidelity fidelity does not endorse or adopt their content fidelity makes no guarantees that information supplied is accurate complete or timely and does not provide any warranties regarding results obtained from their usestock markets especially foreign markets are volatile and can decline significantly in response to adverse issuer political regulatory market or economic developments sector funds can be more volatile because of their narrow concentration in a specific industrysystem availability and response times may be subject to market conditionsthe fidelity screeners are research tools provided to help selfdirected investors evaluate securities the criteria and inputs entered are at the sole discretion of the user and all screens or strategies with preselected criteria are solely for the convenience of the user information supplied or obtained from the screeners is for informational purposes only and should not be considered investment advice or guidance an offer of or a solicitation of an offer to buy or sell securities or a recommendation or endorsement by fidelity of any security or investment strategy fidelity does not endorse or adopt any particular investment strategy or approach to screening or evaluating stocks preferred securities exchange traded products or closed end funds fidelity makes no guarantees that information supplied is accurate complete or timely and does not provide any warranties regarding results obtained from their use determine which securities are right for you based on your investment objectives risk tolerance financial situation and other individual factors and reevaluate them on a periodic basis copyright – fmr llc  all rights reserved  terms of use privacy security site map  unavailable  fidelity investments skip to main content site navigation fidelitycom home customer service open an account refer a friend log in customer service open an account refer a friend log out search fidelitycom accounts  trade portfoliolog in required account positionslog in required tradelog in required active trader prolog in required transferlog in required cash managementlog in required billpaylog in required full viewlog in required profilelog in required account featureslog in required statementslog in required tax information retirement distributionslog in required offer see our featured trading offer learn more planning  advice what we offer financial basics building savings managing  growing wealth retirement life events news  research news watch listlog in required quotes alertslog in required mutual funds stocks fixed income bonds  cds etfs options markets  sectors ipos annuities learning center notebook notebook investment products mutual funds retirement  iras trading stocks fixed income bonds  cds etfs options sector investing cash management  credit cards managed accounts fidelity go  college savings annuities life insurance  long term care why fidelity the fidelity advantage planning  advice trading straightforward pricing insights  tools security  protection customer service open an account refer a friend log in customer service open an account refer a friend log out content and data provided by various third parties and fidelity − terms of use research  stocks  stock details enter company or symbol press down arrow for suggestions or escape to return to entry field view this information for the company or symbol snapshot detailed quote adv chart  technical news  events compare analyst opinions research reports key statistics earnings dividends ownership  insiders financial statements sec filings view this information for the company or symbol snapshot detailed quote advanced chart news analyst reports find symbol opens in new window stock research  ideas stock research center my research screen  filter stock screeners preset expert strategies news  insights events calendar upgrades  downgrades explore firm research research firms research firm scorecards reports search related resources fidelity learning center us markets global markets sectors  industries this feature is temporarily unavailable copyright – fmr llc  all rights reserved  terms of use privacy security site map  nicholas s saccomano  aiea hi  company information products resources my account talk to a db advisor  business directory hi aiea nonclassifiable establishments nonclassifiable establishments nicholas s saccomano n nicholas s saccomano claim this business   keauka loop aiea hi  get directions business info founded  incorporated annual revenue  employee count  industries nonclassifiable establishments contacts  contact business your email address subject message send message company summary nicholas s saccomano is located at   keauka loop in aiea and has been in the business of nonclassifiable establishments since  verified status unverified address unverified last verified  phone unverified payment method unverified view full report similar businesses nearby our similar businesses nearby shows similar businesses in their industry and region based on information found in their dun  bradstreet credibility review profile competitive landscape our competitive landscape shows how this business compares to similar businesses in their industry and region based on information found in their dun  bradstreet credibility review profile payments accepted no data hours sunday   monday   tuesday   wednesday   thursday   friday   saturday   n view additional data select from over  networks below to view available data about this business if this data is unavailable or inaccurate and you own or represent this business click here for more information on how you may be able to correct it credibility review google facebookcom yellowbookcom bingcom yellowpagescom merchantcircle tele atlas tomtom twittercom aol mapquest yahoo local applesiri groupon hotfrogcom comcastnet search reachlocal admedia dealsplus shoptopiacom alteryx dogtime media kslcom sirtune americantownscom driverside kudzucom specialsagentcom answerscom egood lawinfocom spotlikescom anywhocom egumball likenesscom spotzot eservicelog mapmyrun technocom apartmentguidecom ezlocalcom eztousecom teleroute aroundmecom metropolistcom therapistscom atlanta newhomes findlawcom time out new york avantar findthebestcom mojopagescom bb yellowpages fivestar software mycitywaycom tripadvisor bckyrdcom giftcardscom mycouponscom beachcaliforniacom golocalcom mymovecom upmesocialcom belo goodinfo newsgazette nokia usdirectorycom carscom nomao centzycom hibu openlistcom chacha search homeplatecom ownlocalcom visikard challamacom homestore patchcom voltari citybot pelopidas vouchd classifiedads hostway placeiq walkscorecom cloudmade hoodoyou planetdiscovercom weddingwirecom powerprofiles where inc contractorscom igolocalcom radiate media wikiocity couponmap indeedcom wimgocom crowdspot innova electronics intellistrand realtorcom datasphere inthemocom replycom yellowbotcom jiwire rocket fuel yellowpagecitycom dmvorg justclicklocalcom dirxion keencom zidstercom photos business credit report receive a onetime comprehensive credit report on this company get full credit report facebook twitter yelp call  to speak with a db advisor today customer resources products education center business articles  insights glossary contact us customer support communication preferences search for db duns our company about us company history business credit history careers press releases news success stories hoovers our network partners affiliates blog access to capital entrepreneurial initiative db international supplieredge site links business directory site map pipeda privacy policy website terms of service product license agreement  dun  bradstreet inc  all rights reserved microsoft personalized ad preferences to opt out of personalized ads in this browser your browser history must allow firstparty and thirdparty cookies and you must have your browsing experience set to not delete browsing history on exit instructions for enabling cookies and configuring your browsing history may be available in your browsers settings privacy or help documentation sign in hold on… we’re sorry but this didn’t work you can’t turn off personalized ads right now because your browser is currently blocking thirdparty cookies we can help you fix this issue let’s get started depending on what browser you use open options or settings make sure that thirdparty cookies are not blocked anymore to find out how search your browser’s help revisit httpchoicemicrosoftcomoptout and then on the “personalized ads in this browser” tile click off ext about our ads to create a more customized online experience some of the ads you may receive on microsoft websites and apps are tailored to your previous activities searches and site visits youre in control and heres where you can make the advertising choice thats right for you ext where can i learn more about advertising on microsoft websites and apps microsoft partners with oath appnexus and other third party service providers to help present customized content and display advertisements on msn outlookcom and other websites and apps microsoft also delivers search ads to bing and our search syndication partners learn more about microsoft’s privacy practices here you can learn more about interestbased ads from oath and appnexus in their privacy statements oath and appnexus what choices do i have about interestbased advertising on this page you can opt out of receiving interest based advertising from microsoft you can also opt out of receiving interestbased advertising from all selfregulatory members including microsoft oath appnexus and other third party ad networks at the following sites in the us digital advertising alliance daa in europe european interactive digital advertising alliance edaa in canada ad choices digital advertising alliance of canada daac you can control interestbased advertising in windows apps by turning off the advertising id in windows settings more choices do you want personalized ads from other companies questions if you have a privacy question or a question for the chief privacy officer of microsoft please contact us by using our web form we will respond to questions within  days ext personalized ads in this browser off optout is currently unavailable please try again later control the personalized ads setting for this web browser learn more if you want microsoft to show ads that might be relevant to you click on to show “generic” ads click off ext personalized ads wherever i use my microsoft account off sign in to change optout is currently unavailable please try again later control the personalized ads setting that applies when you are signed in on any computer or device with your microsoft account including windows windows phone xbox and other devices learn more if you want microsoft to show ads that might be relevant to you click on to show “generic” ads click off if you choose “generic” ads and use a browser your choice applies to everyone when using that browser as long as you do not clear your cookies ext personalized ads in windows in your windows settings you can turn off personalized ads that appear in apps on this device you’ll still see ads but they won’t be personalized anymore if you have windows  access the charms by touching or moving your pointer to the right edge of the screen click or tap settings and then click or tap change pc settings click or tap privacy and then turn off let apps use my advertising id for experiences across apps if you have windows  click or tap the start button click or tap settings click or tap privacy and then turn off let apps use my advertising id for experiences across apps if you have a windows mobile device go to settings tap on privacy tap on advertising id and then turn off let apps use my advertising id for experiences across apps if you want to turn off personalized ads from microsoft wherever you use your microsoft account including apps on windows windows phone xbox and other devices you can do so by selecting the microsoft account option above ext legal privacy  cookies   microsoft arry stock news  fidelity skip to main content site navigation fidelitycom home customer service open an account refer a friend log in customer service open an account refer a friend log out search fidelitycom accounts  trade portfoliolog in required account positionslog in required tradelog in required active trader prolog in required transferlog in required cash managementlog in required billpaylog in required full viewlog in required profilelog in required account featureslog in required statementslog in required tax information retirement distributionslog in required offer see our featured trading offer learn more planning  advice what we offer financial basics building savings managing  growing wealth retirement life events news  research news watch listlog in required quotes alertslog in required mutual funds stocks fixed income bonds  cds etfs options markets  sectors ipos annuities learning center notebook notebook investment products mutual funds retirement  iras trading stocks fixed income bonds  cds etfs options sector investing cash management  credit cards managed accounts fidelity go  college savings annuities life insurance  long term care why fidelity the fidelity advantage planning  advice trading straightforward pricing insights  tools security  protection customer service open an account refer a friend log in customer service open an account refer a friend log out content and data provided by various third parties and fidelity − terms of use research  stocks  stock details enter company or symbol press down arrow for suggestions or escape to return to entry field view this information for the company or symbol snapshot detailed quote adv chart  technical news  events compare analyst opinions research reports key statistics earnings dividends ownership  insiders financial statements sec filings view this information for the company or symbol snapshot detailed quote advanced chart news analyst reports find symbol opens in new window snapshot detailed quote advanced chart  technical analysis news  events compare analyst opinions research reports key statistics earnings dividends ownership  insiders financial statements sec filings related resources stock research overview stock screeners markets  sectors fidelity learning center print  helpglossary helpglossary news  eventsarry array biopharma inc    as of pm et  quotes delayed at least  min log in for real time quote add to watch list set alert hypothetical trade option chain price history download to csv file download to excel file log in for more news expand all collapse all technical reports on biotech equities  opko health array biopharma immunomedics and tg therapeutics pr newswire –  am et  new york july   if you want a stock review on opk arry immu or tgtx then come over to httpdailystocktrackercomregister and sign up for your free customized report today httpdailystocktrackercomregister opko health  on wednesday shares in miami florida headquartered opko health inc opk gained  ending the day at  the stock recorded a trading volume of  mill briefamgen and array biopharma announce preclinical license and collaboration agreement reuters –  am et  array biopharma inc arry  amgen amgn and array biopharma arry announce preclinical license and collaboration agreement in inflammation  array biopharma arry  under terms of agreement amgen amgn and array will collaborate on preclinical development with array leading medicinal chemistry work amgen and array biopharma announce preclinical license and collaboration agreement in inflammation pr newswire –  am et  thousand oaks calif and boulder colo we are pleased to enter this collaboration with array that builds on our continued focus in inflammation one of amgens amgn key strategic areas of interest said flavius martin md vice president of research inflammation and oncology at amgen pharma stocks taking measures to boost growth pr newswire –  am et  palm beach florida july   biotech and big pharma stocks have been a tear of late causing the spdr sp biotech etf to edge towards annual highs briefarray biopharma submits new drug applications to fda reuters –  am et  array biopharma inc arry  array biopharma arry submits new drug applications to fda for binimetinib and encorafenib in advanced melanoma array biopharma submits new drug applications to fda for binimetinib and encorafenib in advanced melanoma pr newswire –  am et  boulder colo premarket technical recap on biotech stocks  array biopharma catabasis pharma cerulean pharma and immunomedics pr newswire –  am et  new york june   if you want a stock review on arry catb ceru or immu then come over to httpdailystocktrackercomregister and sign up for your free customized reports today httpdailystocktrackercomregister array biopharma  boulder colorado headquartered array biopharma incs arry shares surged  finishing tuesdays trading session at  a total volume of  millio array biopharma to present at the goldman sachs th annual global healthcare conference pr newswire –  am et  boulder colo about array biopharma arry array biopharma inc arry is a biopharmaceutical company focused on the discovery development and commercialization of targeted small molecule drugs to treat patients afflicted with cancer briefono pharmaceutical concludes a license agreement with array biopharma related to mek inhibitor and braf inhibitor reuters –  am et  ono pharmaceutical co ltd ophlf  says it concluded a license agreement with array biopharma inc arry to develop and commercialize binimetinib a mek inhibitor and encorafenib a braf inhibitor in japan and south korea briefarray biopharma  ono pharmaceutical announce partnership for two novel oncology compounds reuters –  am et  array biopharma inc arry  array biopharma arry  ono pharmaceutical co ltd announce license development  commercialization partnership for  novel oncology compounds binimetinib and encorafenib  array biopharma arry says array to receive  million upfront payment and up to  million in additional development and commercial milestones array biopharma and ono pharmaceutical co ltd announce a license development and commercialization partnership for two novel oncology compounds binimetinib and encorafenib pr newswire –  am et  boulder colo and osaka japan  array biopharma inc arry and ono pharmaceutical co ltd today announced a license development and commercialization partnership for arrays latestage novel oncology compounds binimetinib and encorafenib  million and retains exclusive commercialization rights for binimetinib and encorafenib in the united states canada and israel briefarray biopharma and bristolmyers squibb announce strategic collaboration reuters –  am et  array biopharma inc arry  array biopharma and bristolmyers squibb bmy announce strategic collaboration  bristolmyers squibb co bmy says under terms of agreement array and bristolmyers squibb bmy will jointly support study with array acting as sponsor  bristolmyers squibb co bmy  collaboration to investigate safety tolerability and efficacy of arrays investigational mek inhibitor binimetinib array bipharma shares jump  in premarket trade marketwatch –  am et  array biopharma and bristolmyers to collaborate on treatment for colorectal cancer marketwatch –  am et  array biopharma and bristolmyers squibb announce strategic collaboration pr newswire –  am et  boulder colo opdivo as well as binimetinib in combination with the opdivo  yervoy regimen under the terms of the agreement array and bristolmyers squibb bmy will jointly support the study with array acting as the sponsor array biopharma and bristolmyers squibb announce strategic collaboration business wire –  am et  novel combinations of binimetinib opdivo® and yervoy® to be studied in colorectal cancer patients array biopharma arry and bristolmyers squibb company today announced the companies have entered into a clinical research collaboration to investigate the safety tolerability and efficacy of array’s investigational mek inhibitor binimetinib in combination with bristolmyers squibb’s opdivo and  briefarray biopharma q loss per share  reuters –  am et  array biopharma inc arry  array biopharma reports financial results for the third quarter of fiscal   q loss per share   q earnings per share view   thomson reuters ibes  q revenue  million versus ibes view  million  array biopharma inc arry  is on track to file an nda for columbus in june or july  array biopharma reports financial results for the third quarter of fiscal  pr newswire –  am et  boulder colo columbus phase  trial positive part  results announcedon may   array announced topline results from part  of the phase  columbus study evaluating binimetinib a mek inhibitor and encorafenib a braf inhibitor in patients with brafmutant advanced unresectable or metastatic melanoma briefarray biopharma announces positive topline results from part  of the phase  columbus study of binimetinib and encorafenib reuters –  pm et  array biopharma inc arry  array biopharma arry announces positive topline results from part  of the phase  columbus study of binimetinib and encorafenib for brafmutant melanoma  array biopharma inc arry  new drug application filing on track for june or july   array  median pfs for patients on combination of binimetinib plus encorafenib  months versus  months for patients on encorafenib array biopharma announces positive topline results from part  of the phase  columbus study of binimetinib and encorafenib for brafmutant melanoma pr newswire –  pm et  boulder colo brafmutant melanoma said keith t flaherty md director of the termeer center for targeted therapy massachusetts general hospital and professor of medicine harvard medical school page page   next  todays and upcoming events aug  arry to announce q earnings before market unconfirmed past events last  days no events in the past  days data provided by wall street horizon inc   technical events classic patterns past  days provided by recognia inc log in for trading events view all technical analysis in advanced chart technical analysis provided by trading central log in for trading events as with all your investments through fidelity you must make your own determination whether an investment is appropriate for you fidelity is not recommending or endorsing this security by making it available to customers you should conduct research and perform a thorough investigation as to the characteristics of any securities you intend to purchase before investing you should read the prospectus offering circular indenture or similar document carefully for a full description of the product including its features and risks to determine whether it is an appropriate investment for your investment objectives risk tolerance financial situation and other individual factors and be sure to reevaluate those factors on a periodic basisperformance data shown represents past performance which is no guarantee of future results current performance may be higher or lower than the performance data quoted yield and return will vary therefore you may have a gain or loss when you sell your sharesstock markets are volatile and can decline significantly in response to adverse issuer political regulatory market or economic developments growth stocks can be more volatile than other types of stocks value stocks can continue to be undervalued by the market for long periods of time foreign securities are subject to interestrate currencyexchangerate economic and political risks all of which are magnified in emerging markets illiquidity is an inherent risk associated with investing in real estate and reits there is no guarantee the issuer of a reit will maintain the secondary market for its shares and redemptions may be at a price which is more or less than the original price paid closedend funds can trade at a discount to their nav shareholders of master limited partnerships may be treated as partners for tax purposes partnerships issue a schedule k form  rather than a form  form for tax purposes it lists the partners share of income deductions credits etc speak with your tax advisor to determine how this may affect you a royalty trust is a type of corporation mostly in the united states or canada usually involved in oil and gas production or mining royalty trusts may have special tax treatment so you should consult a tax advisor on the potential tax consequences of investing in themnews commentary and events are from thirdparty sources unaffiliated with fidelity fidelity does not endorse or adopt their content fidelity makes no guarantees that information supplied is accurate complete or timely and does not provide any warranties regarding results obtained from their useany data charts and other information provided on this page are intended for research purposes to help selfdirected investors evaluate many types of securities including but not limited to common stocks american depository receipts master limited partnerships real estate investment trusts traditional preferred stock trust preferred securities thirdparty trust certificates convertible securities mandatory convertible securities and other exchangetraded equity andor debt securities criteria and inputs entered including the choice to make security comparisons are at the sole discretion of the user and are solely for the convenience of the user analyst opinions ratings and reports are provided by thirdparties unaffiliated with fidelity all information supplied or obtained from this page is for informational purposes only and should not be considered investment advice or guidance an offer of or a solicitation of an offer to buy or sell a security or a recommendation or endorsement by fidelity of any security or investment strategy fidelity does not endorse or adopt any particular investment strategy any analyst opinionratingreport or any approach to evaluating individual securities fidelity makes no guarantees that information supplied is accurate complete or timely and does not provide any warranties regarding results obtained from its use copyright – fmr llc  all rights reserved  terms of use privacy security site map  see the latest features personalizedget relevant information about your holdings right when you need itsee your performance click the portfolio icon to get information about stocks you own without leaving the research pagefaster access to positions a shortcut to view the full list of positions in your portfolio yes please use the ticker search boxadd your own notes use notebook to save your investment ideas in one convenient private and secure place convenient for youresearch thats clear accessible and all in one place makes for a better experienceonestop shop see everything you need to make investment decisions right in the dashboardaccess anywhere no matter where you are use the stock research experience across multiple devicesnew ideas on the ready find new ideas using quick links to the stock screener new ways to researchdiscover new tools to add or diversify your existing research strategystocktwits read live tweets from the financial and investing community about the stock youre interested infundamental analysis save time on research by getting an overall assessment of a companys valuation quality growth stability and financial healthrecognia technical analysis perfect for the technical trader—this indicator captures a stocks technical events and converts them into short medium and longterm sentimenttop competitors see how a stock measures up by instantly comparing it to the industry average and its top four competitorssocial sentiment get a sense of peoples overall feelings towards a company in social media with this summary toolearnings data monitor earnings expectations over the past three quarters and model a stocks price based on its pe msc industrial direct – all product categories welcome to msc this site is screen reader friendly skip to the page header skip to the main navigation skip to the page content skip to the page footer help chat about us   sign in toyour account or register username forgot username password retrieve password login remember username dont have a login register products all products ecofriendly products exclusive brands new products request a quote supplier listing featured lines lighting machinery safety solutions inventory management case studies ebusiness government lean environment metalworking national accounts pcards resources technical informationbasics of case studies ecofriendly education lamps  legislation metalworking utilites website features special offers monthly sales flyers clearance specials emergency preparedness hvac new technology rebates shipping  packaging summer shutdown web specials catalogs big book annual catalogs metalworking v safety monthly sales flyers maintenance  repair metalworking super savers package stuffers and more inventory clearance shop  save view all catalogs  brochures better mro quick order pad please add at least one part  please enter valid partnumber and quantity add to cart large order pad all product categories please choose from the categories below to refine your search abrasives clamping workholding  positioning fasteners fleet maintenance hvac hand tools hardware holemaking hose tube fittings  valves indexable cutting tools janitorial  facility maintenance lighting  electrical lubricants coolants  fluids machinery marking  labeling material handling  storage measuring  inspecting milling motion control  fluid power plumbing pumps  filtration power tools raw materials safety saw blades shipping  office supplies tapes  adhesives threading tool holding turning  boring welding  soldering product categories abrasives clamping workholding  positioning fasteners fleet maintenance hvac hand tools hardware holemaking hose tube fittings  valves indexable cutting tools janitorial  facility maintenance lighting  electrical lubricants coolants  fluids machinery marking  labeling material handling  storage measuring  inspecting milling motion control  fluid power plumbing pumps  filtration power tools raw materials safety saw blades shipping  office supplies tapes  adhesives threading tool holding turning  boring welding  soldering about msc events press releases investor relations community relations career opportunities customer service contact us return policy shipping options website terms of use help  support faqs how to use our site locate sds invoicing  credit get the latest deals and news from msc sign up by submitting your email address you consent to receive electronic communications from msc industrial direct co inc site map  terms and conditions of sale  privacy policy     msc industrial direct co inc all rights reserved executive qa nicholas saccomano cso of array biopharma search search home newsnewspharmaceutical newsbiotechnology newsgenerics newsbiosimilars newsmergers  acquisitionsregulationworld newstop news stories combo approved in eu across major hcv genotypesbiotechnologykeytruda key to merck  co’s estimatetopping profitspharmaceutical in depthin depthanalysisspecial reportinterviewin conversation with expert viewfrom our correspondentin the boardroomtop in depth stories after  years of failure what can pharma offer alzheimers patientspharmaceuticalpatient centricity making clinical trials more effective by keeping focus on the patientpharmaceutical conference roundupconference roundupaaic eular easl asco aacr annual meeting ectrims top conference roundup stories combo approved in eu across major hcv genotypesbiotechnologykeytruda key to merck  co’s estimatetopping profitspharmaceutical focus onfocus onbrexitfdapricingemarussian markettrump administrationtop focus on stories inquiry asks how to stimulate uk life sciences innovationpharmaceuticalbrexit and longerterm sector trends could boost uk pharma mainvestmentbiotechnology events companies reports executive qa nicholas saccomano cso of array biopharma  comments print more on this storyarticlearray biopharma inks deal with biogen idec on autoimmune disordersother stories of interestarticlecombo approved in eu across major hcv genotypesarticlekeytruda key to merck  co’s estimatetopping profitsarticlehumira still boosting abbvie’s results which beat expectationsin contextarticleanthera appoints chuck olson as president of alkiraarticlebreakthrough therapy designation likely to positively influence oncologistsarticlefda accepts teva’s nda for albuterol mdpirelated news from the webnewsnew d imaging reveals how human cell nucleus organizes dna and chromatin of its genomenewsbiochemists link synthetic compound to hungerhormone productionnewsquantel medical receives fda approval for easyret photocoagulator laserrelated peopleron squarerrelated companiesarray biopharmain an interview with the pharma letter nicholas saccomano chief science officer of array biopharma…to continue reading this article and to access exclusive features interviews roundups and commentary from the sharpest minds in the pharmaceutical and biotechnology space you need to be logged into the site and have an active subscription or trial subscription  please login or subscribe in order to continue reading claim a weeks trial subscription by signing up for free today and receive our daily pharma and biotech news bulletin free of charge foreverarray biopharmabiogen idecbiotechnologyhealth medical pharmain depthinterviewsmelanomaoncologyprotein kinase inhibitorusamore on this storyarticlearray biopharma inks deal with biogen idec on autoimmune disordersother stories of interestarticlecombo approved in eu across major hcv genotypesarticlekeytruda key to merck  co’s estimatetopping profitsarticlehumira still boosting abbvie’s results which beat expectationsin contextarticleanthera appoints chuck olson as president of alkiraarticlebreakthrough therapy designation likely to positively influence oncologistsarticlefda accepts teva’s nda for albuterol mdpirelated news from the webnewsnew d imaging reveals how human cell nucleus organizes dna and chromatin of its genomenewsbiochemists link synthetic compound to hungerhormone productionnewsquantel medical receives fda approval for easyret photocoagulator laserrelated peopleron squarerrelated companiesarray biopharma take a free trial what you get access the pharma letters latest news free for  days plus you can receive the pharma letter headlines and news roundup email free forever click here to take a free trial become a subscriber what you get unlimited access to the pharma letter site for a whole year only £ per month or £ per year nolimits access to our site with uptothe minute news personalised news and email alerts online discussion forums and qa section rss news feeds that you can add to your favourite reader or website daily news email alert with the breaking news stories and news roundup click here to subscribe “pharma letter is an extremely useful and valuable life sciences service that brings together a daily update on performance people and products its part of the key information for keeping me informed” nigel brooksby chairman sanofi aventis uk ltd sign up for our daily newsletter our latest news direct to your inbox newsletter back to top